ASXL2 (ASXL transcriptional regulator 2)

2012-11-01  

Identity

HGNC
LOCATION
2p23.3
LOCUSID
ALIAS
ASXH2,SHAPNS
FUSION GENES

Other Information

Locus ID:

NCBI: 55252
MIM: 612991
HGNC: 23805
Ensembl: ENSG00000143970

Variants:

dbSNP: 55252
ClinVar: 55252
TCGA: ENSG00000143970
COSMIC: ASXL2

RNA/Proteins

Gene IDTranscript IDUniprot
ENSG00000143970ENST00000336112E7EWD6
ENSG00000143970ENST00000404843Q76L83
ENSG00000143970ENST00000435504Q76L83

Expression (GTEx)

0
5
10
15
20

Pathways

PathwaySourceExternal ID
Metabolism of proteinsREACTOMER-HSA-392499
Post-translational protein modificationREACTOMER-HSA-597592
DeubiquitinationREACTOMER-HSA-5688426
UCH proteinasesREACTOMER-HSA-5689603

References

Pubmed IDYearTitleCitations
337313622021Kinetic Characterization of ASXL1/2-Mediated Allosteric Regulation of the BAP1 Deubiquitinase.1
337517732021Understanding the phenotypic spectrum of ASXL-related disease: Ten cases and a review of the literature.7
338124142021[The Relationship between ASXL2 and ZBTB7A Gene Mutations and Prognosis in Patients with Acute Myeloid Leukemia].0
337313622021Kinetic Characterization of ASXL1/2-Mediated Allosteric Regulation of the BAP1 Deubiquitinase.1
337517732021Understanding the phenotypic spectrum of ASXL-related disease: Ten cases and a review of the literature.7
338124142021[The Relationship between ASXL2 and ZBTB7A Gene Mutations and Prognosis in Patients with Acute Myeloid Leukemia].0
320272642020[Relation of ASXL2 Gene Mutation with Clinical Characteristics, Prognosis and C-KIT Gene Mutation in AML Patients with AML1- ETO Fusion Gene].0
329454272020Association between serum anti‑ASXL2 antibody levels and acute ischemic stroke, acute myocardial infarction, diabetes mellitus, chronic kidney disease and digestive organ cancer, and their possible association with atherosclerosis and hypertension.12
320272642020[Relation of ASXL2 Gene Mutation with Clinical Characteristics, Prognosis and C-KIT Gene Mutation in AML Patients with AML1- ETO Fusion Gene].0
329454272020Association between serum anti‑ASXL2 antibody levels and acute ischemic stroke, acute myocardial infarction, diabetes mellitus, chronic kidney disease and digestive organ cancer, and their possible association with atherosclerosis and hypertension.12
302512052019Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study.15
316374842019ASXL2 mutation is recurrent in non-de novo AML1-ETO-negative acute myeloid leukemia.1
302512052019Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study.15
316374842019ASXL2 mutation is recurrent in non-de novo AML1-ETO-negative acute myeloid leukemia.1
292847402018Familial and Somatic BAP1 Mutations Inactivate ASXL1/2-Mediated Allosteric Regulation of BAP1 Deubiquitinase by Targeting Multiple Independent Domains.12

Citation

Dessen P

ASXL2 (ASXL transcriptional regulator 2)

Atlas Genet Cytogenet Oncol Haematol. 2012-11-01

Online version: http://atlasgeneticsoncology.org/gene/52971/asxl2-(asxl-transcriptional-regulator-2)